Simulations Plus (NASDAQ: SLP) agrees to a $375 million all-cash buyout by healthcare-focused private equity firm Altaris, offering shareholders $18.50 per share.

Key Highlights

  • Altaris will pay $18.50 per share in cash for Simulations Plus (NASDAQ: SLP), valuing the deal at $375 million.
  • The transaction is expected to close in the fourth quarter of 2026, pending shareholder and regulatory approval.
  • Simulations Plus will merge with Altaris portfolio company Chemical Computing Group post-acquisition.
  • The company will delist from NASDAQ and operate as a private entity under Altaris ownership.

Shareholders will receive $18.50 per share, a 26% premium over the company’s 60-day volume-weighted average price.

The deal, unanimously approved by Simulations Plus’ board, positions the company for accelerated growth through integration with Chemical Computing Group, an existing Altaris portfolio company.

Chemical Computing Group, founded in 1994, provides molecular design software to pharmaceutical and biotechnology firms.

The combined entity aims to strengthen offerings in AI-driven drug development and model-informed pharmaceutical solutions.

The firm’s strategy focuses on scaling companies through operational improvements and strategic mergers.

Simulations Plus, a leader in computational drug development tools, will retain its headquarters in Research Triangle Park, North Carolina, post-acquisition.

The transaction is structured without financing contingencies, backed by committed equity and debt from Altaris-affiliated funds.

Shareholder approval and regulatory clearances remain key closing conditions, with completion targeted for the fourth quarter of 2026.

Upon finalization, Simulations Plus will delist from NASDAQ and operate as a private subsidiary of Altaris.

Simulations Plus will release its third-quarter fiscal 2026 financial results on July 9, 2026, but will not hold an earnings call during the pending transaction.

The company’s co-founder, Dr.

Walter Woltosz, has agreed to vote his shares in favor of the deal, reinforcing board support.

The acquisition reflects broader consolidation trends in healthcare technology, where private equity firms are increasingly targeting software providers with recurring revenue models.

Altaris’ focus on integrating complementary assets could reshape competitive dynamics in the drug development software sector.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.